慢性肾脏病的丙型肝炎病毒感染的预防,诊断,评估和治疗指南2019

2019-09-27 肾脏病相关专家小组(统称) Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539

肾脏疾病:改善全球结局(KDIGO)2018临床实践指南,用于预防,诊断,评估和治疗慢性肾脏病(CKD)中的丙型肝炎病毒(HCV)感染,是KDIGO 2008年关于HCV感染指南的广泛更新在CKD中。此更新反映了自从在CKD人群中HCV感染管理中引入直接作用抗病毒药物(DAA)以来的重大进展。方法:KDIGO工作组负责制定HCV和CKD指南,定义了指南的范围,收集了证据,确定了要进行系统审查的主题

中文标题:

慢性肾脏病的丙型肝炎病毒感染的预防,诊断,评估和治疗指南2019

英文标题:

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline.

发布日期:

2019-09-27

简要介绍:

肾脏疾病:改善全球结局(KDIGO)2018临床实践指南,用于预防,诊断,评估和治疗慢性肾脏病(CKD)中的丙型肝炎病毒(HCV)感染,是KDIGO 2008年关于HCV感染指南的广泛更新在CKD中。此更新反映了自从在CKD人群中HCV感染管理中引入直接作用抗病毒药物(DAA)以来的重大进展。

方法:
KDIGO工作组负责制定HCV和CKD指南,定义了指南的范围,收集了证据,确定了要进行系统审查的主题,并对证据审查小组先前总结的证据质量进行了分级。使用GRADE(建议分级评估,制定和评估)方法来评估证据的质量并评估建议的强度。截至2017年5月,对英语文献进行了搜索,并以针对性的搜索方式进行了DAA治疗研究以及肾脏病学,肝病学和移植会议的摘要作为补充。涉及许多利益相关者,主题专家以及行业和国家组织的评审过程为指南的最终修改提供了依据。

建议:
更新后的指南包含66条建议。本概要着重于与成人CKD人群的HCV感染的预防,诊断,治疗和管理有关的32个关键建议。

相关资料下载:
[AttachmentFileName(sort=100, fileName=慢性肾脏病的丙型肝炎病毒感染的预防,诊断,评估和治疗指南2019)] GetToolGuiderByIdResponse(projectId=1, id=842781c001e962ee, title=慢性肾脏病的丙型肝炎病毒感染的预防,诊断,评估和治疗指南2019, enTitle=Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline., guiderFrom=Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539, authorId=null, author=, summary=肾脏疾病:改善全球结局(KDIGO)2018临床实践指南,用于预防,诊断,评估和治疗慢性肾脏病(CKD)中的丙型肝炎病毒(HCV)感染,是KDIGO 2008年关于HCV感染指南的广泛更新在CKD中。此更新反映了自从在CKD人群中HCV感染管理中引入直接作用抗病毒药物(DAA)以来的重大进展。方法:KDIGO工作组负责制定HCV和CKD指南,定义了指南的范围,收集了证据,确定了要进行系统审查的主题, cover=, journalId=null, articlesId=null, associationId=283, associationName=肾脏病相关专家小组(统称), associationIntro=本制定者非特指某个专家小组。, copyright=0, guiderPublishedTime=Fri Sep 27 03:31:15 CST 2019, originalUrl=, linkOutUrl=, content=<div>肾脏疾病:改善全球结局(KDIGO)2018临床实践指南,用于预防,诊断,评估和治疗慢性肾脏病(CKD)中的丙型肝炎病毒(HCV)感染,是KDIGO 2008年关于HCV感染指南的广泛更新在CKD中。此更新反映了自从在CKD人群中HCV感染管理中引入直接作用抗病毒药物(DAA)以来的重大进展。</div><div><br></div><div>方法:</div><div>KDIGO工作组负责制定HCV和CKD指南,定义了指南的范围,收集了证据,确定了要进行系统审查的主题,并对证据审查小组先前总结的证据质量进行了分级。使用GRADE(建议分级评估,制定和评估)方法来评估证据的质量并评估建议的强度。截至2017年5月,对英语文献进行了搜索,并以针对性的搜索方式进行了DAA治疗研究以及肾脏病学,肝病学和移植会议的摘要作为补充。涉及许多利益相关者,主题专家以及行业和国家组织的评审过程为指南的最终修改提供了依据。</div><div><br></div><div>建议:</div><div>更新后的指南包含66条建议。本概要着重于与成人CKD人群的HCV感染的预防,诊断,治疗和管理有关的32个关键建议。</div>, tagList=[TagDto(tagId=482, tagName=肾脏), TagDto(tagId=589, tagName=丙型肝炎)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2851, appHits=188, showAppHits=5, pcHits=1571, showPcHits=1841, likes=43, shares=4, comments=5, approvalStatus=1, publishedTime=Fri Sep 27 03:31:15 CST 2019, publishedTimeString=2019-09-27, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=fbzhang, createdTime=Fri Sep 27 03:31:15 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:00:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=慢性肾脏病的丙型肝炎病毒感染的预防,诊断,评估和治疗指南2019)])
慢性肾脏病的丙型肝炎病毒感染的预防,诊断,评估和治疗指南2019
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=916013, encodeId=43219160137c, content=急需积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0311569535, createdName=282082690, createdTime=Tue Jan 12 20:09:01 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891716, encodeId=26d4891e1604, content=打开好好学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d901889741, createdName=ms7792044158831279, createdTime=Tue Oct 13 10:18:34 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891715, encodeId=77f0891e1593, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d901889741, createdName=ms7792044158831279, createdTime=Tue Oct 13 10:18:16 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2021-01-12 282082690

    急需积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=916013, encodeId=43219160137c, content=急需积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0311569535, createdName=282082690, createdTime=Tue Jan 12 20:09:01 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891716, encodeId=26d4891e1604, content=打开好好学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d901889741, createdName=ms7792044158831279, createdTime=Tue Oct 13 10:18:34 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891715, encodeId=77f0891e1593, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d901889741, createdName=ms7792044158831279, createdTime=Tue Oct 13 10:18:16 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-10-13 ms7792044158831279

    打开好好学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=916013, encodeId=43219160137c, content=急需积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0311569535, createdName=282082690, createdTime=Tue Jan 12 20:09:01 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891716, encodeId=26d4891e1604, content=打开好好学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d901889741, createdName=ms7792044158831279, createdTime=Tue Oct 13 10:18:34 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891715, encodeId=77f0891e1593, content=挺好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d901889741, createdName=ms7792044158831279, createdTime=Tue Oct 13 10:18:16 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-10-13 ms7792044158831279

    挺好的

    0